Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ireland-based Azur Pharma has licensed the exclusive US marketing rights for Niravam, Parcopa, Kemstro and Fluxid from UCB, a Belgium-based biopharmaceutical company. Financial terms were not disclosed.
Subscribe to our email newsletter
Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets) and Kemstro (baclofen orally disintegrating tablets) are central nervous system (CNS) products.
Niravam and Parcopa have been commercially available in the US since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Kemstro and Fluxid are both FDA approved but not yet commercially available in the US.
Seamus Mulligan, chairman and CEO of Azur, said: “We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value-added drug delivery technologies.”